Differentiation therapy for glioblastoma - too many obstacles?
The therapeutic potential of differentiation therapy for glioblastoma will depend on the robustness and stability of the differentiated state. We recently reported several obstacles to bone morphogenetic protein (BMP)-induced differentiation therapy. Improved understanding of the mechanisms that tumor cells use to escape differentiation commitment is urgently needed.
Sahlgrenska Cancer Center, Department of Pathology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg , 405 30 Gothenburg, Sweden.
Helena
H
Carén
Department of Cancer Biology, UCL Cancer Institute, University College London , Paul O'Gorman Building, 72 Huntley Street , London WC1E 6BT, UK.
Stephan
S
Beck
MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh bioQuarter , 5 Little France Drive , Edinburgh EH16 4UU, UK.
Steven M
SM
Pollard
Astrocyte; BMP; DNA methylation; Glioblastoma; differentiation; epigenetics; neural stem cell; oligodendrocyte